low-to-moderate - Medical device procedures are largely non-discretionary (cardiac emergencies, chronic pain management) providing recession resilience. However, elective procedures (some neuromodulation, certain endoscopy cases) can see deferral during severe downturns when patients delay care or lose insurance coverage. Hospital capital equipment purchases may slow in recessions, though BSX is primarily consumables-focused. Aging demographics provide structural tailwind independent of economic cycles.

Rising rates have modest negative impact through two channels: (1) higher discount rates compress valuation multiples for growth stocks, particularly impacting BSX's premium 5.5x P/S multiple; (2) increased debt service costs on $5.7B net debt (0.51 D/E ratio) marginally pressure interest expense, though impact is small given strong cash generation ($3.4B operating cash flow). Hospital customers face higher financing costs for capital investments, potentially slowing adoption of new technologies. Conversely, rising rates often signal economic strength supporting employment-based insurance coverage.

growth - BSX attracts growth investors seeking exposure to healthcare innovation with 20% revenue growth, 56% earnings growth, and expanding margins. The premium 5.5x P/S and 24.8x EV/EBITDA multiples reflect growth expectations rather than value characteristics. Recent 30% decline creates potential entry point for growth-at-reasonable-price investors. Not a dividend play (minimal yield given reinvestment in R&D and M&A).